199 related articles for article (PubMed ID: 37287428)
21. Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial.
Christopoulos P; Bozorgmehr F; Brückner L; Chung I; Krisam J; Schneider MA; Stenzinger A; Eickhoff R; Mueller DW; Thomas M
BMC Cancer; 2021 Jun; 21(1):743. PubMed ID: 34182952
[TBL] [Abstract][Full Text] [Related]
22. Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing.
Yang H; Wen L; Pan Y; Shan C; Hong W; Wang H; Zhou C; Cai L; Zhou C
BMC Cancer; 2022 May; 22(1):580. PubMed ID: 35614407
[TBL] [Abstract][Full Text] [Related]
23. Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review.
Li S; Ke L; Meng X; Zhou H; Zhang X; Wu H; Yu J; Zhang H
Recent Pat Anticancer Drug Discov; 2021; 16(1):108-116. PubMed ID: 33245275
[TBL] [Abstract][Full Text] [Related]
24. Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients.
Janke F; Angeles AK; Riediger AL; Bauer S; Reck M; Stenzinger A; Schneider MA; Muley T; Thomas M; Christopoulos P; Sültmann H
Clin Epigenetics; 2022 Dec; 14(1):163. PubMed ID: 36461127
[TBL] [Abstract][Full Text] [Related]
25. Highly sensitive fusion detection using plasma cell-free RNA in non-small-cell lung cancers.
Hasegawa N; Kohsaka S; Kurokawa K; Shinno Y; Takeda Nakamura I; Ueno T; Kojima S; Kawazu M; Suehara Y; Ishijima M; Goto Y; Kojima Y; Yonemori K; Hayashi T; Saito T; Shukuya T; Takahashi F; Takahashi K; Mano H
Cancer Sci; 2021 Oct; 112(10):4393-4403. PubMed ID: 34310819
[TBL] [Abstract][Full Text] [Related]
26. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Wang W; Sun X; Hui Z
Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
[TBL] [Abstract][Full Text] [Related]
27. Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series.
Metro G; Lunardi G; Bennati C; Chiarini P; Sperduti I; Ricciuti B; Marcomigni L; Costa C; Crinò L; Floridi P; Gori S; Chiari R
J Neurooncol; 2016 Sep; 129(2):355-61. PubMed ID: 27324494
[TBL] [Abstract][Full Text] [Related]
28. Attenuated isolated 3' signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC.
Smuk G; Pajor G; Szuhai K; Morreau H; Kocsmár I; Kocsmár É; Pajor L; Kajtár B; Sárosi V; Lotz G; Tornóczky T
Lung Cancer; 2020 May; 143():80-85. PubMed ID: 32272316
[TBL] [Abstract][Full Text] [Related]
29. Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment.
Bordi P; Tiseo M; Rofi E; Petrini I; Restante G; Danesi R; Del Re M
Clin Lung Cancer; 2017 Nov; 18(6):692-697. PubMed ID: 28601386
[TBL] [Abstract][Full Text] [Related]
30. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
31. Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLC.
Kuang Y; Xu P; Wang J; Zheng Y; Sun X; Li Z; Gan R; Li H; Guo Y; Yao F; Zhu C; Ke Z; Tang K
Mol Diagn Ther; 2021 Jul; 25(4):487-494. PubMed ID: 34133003
[TBL] [Abstract][Full Text] [Related]
32. Unique genomic profiles obtained from cerebrospinal fluid cell-free DNA of non-small cell lung cancer patients with leptomeningeal metastases.
Ying S; Ke H; Ding Y; Liu Y; Tang X; Yang D; Li M; Liu J; Yu B; Xiang J; Mao X; Han-Zhang H; Hu W; Chen L
Cancer Biol Ther; 2019; 20(4):562-570. PubMed ID: 30395779
[TBL] [Abstract][Full Text] [Related]
33. Intracranial disease control for EGFR-mutant and ALK-rearranged lung cancer with large volume or symptomatic brain metastases.
Dutta SW; Mack ML; Aliotta E; Ward KA; Muller DA; Larner JM; Fadul CE; Hall RD; Gentzler RD; Sheehan JP
J Neurooncol; 2020 Sep; 149(2):357-366. PubMed ID: 32902767
[TBL] [Abstract][Full Text] [Related]
34. Cerebrospinal fluid-derived circulating tumor DNA is more comprehensive than plasma in NSCLC patients with leptomeningeal metastases regardless of extracranial evolution.
Yang H; Wen L; Zhao C; Chen J; Zhou Z; Zhou C; Cai L; Zhou C
Heliyon; 2022 Dec; 8(12):e12374. PubMed ID: 36643302
[TBL] [Abstract][Full Text] [Related]
35. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.
Camidge DR; Kim DW; Tiseo M; Langer CJ; Ahn MJ; Shaw AT; Huber RM; Hochmair MJ; Lee DH; Bazhenova LA; Gold KA; Ou SI; West HL; Reichmann W; Haney J; Clackson T; Kerstein D; Gettinger SN
J Clin Oncol; 2018 Sep; 36(26):2693-2701. PubMed ID: 29768119
[TBL] [Abstract][Full Text] [Related]
36. Detection of tumor-derived cell-free DNA in cerebrospinal fluid using a clinically validated targeted sequencing panel for pediatric brain tumors.
Ronsley R; Karvonen KA; Cole B; Paulson V; Stevens J; Crotty EE; Hauptman J; Lee A; Stasi SM; Lockwood CM; Leary SES
J Neurooncol; 2024 Jun; 168(2):215-224. PubMed ID: 38755519
[TBL] [Abstract][Full Text] [Related]
37. Cerebrospinal fluid ctDNA testing shows an advantage over plasma ctDNA testing in advanced non-small cell lung cancer patients with brain metastases.
Liu X; Mei F; Fang M; Jia Y; Zhou Y; Li C; Tian P; Lu C; Li G
Front Oncol; 2023; 13():1322635. PubMed ID: 38269023
[TBL] [Abstract][Full Text] [Related]
38. Molecular characteristics and prognostic factors of leptomeningeal metastasis in non-small cell lung cancer.
Liu X; Li G; Zhang H; Chang Q; Fang M; Lu C; Tian P; Mei F
Clin Neurol Neurosurg; 2023 Feb; 225():107572. PubMed ID: 36610238
[TBL] [Abstract][Full Text] [Related]
39. NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.
Sánchez-Herrero E; Serna-Blasco R; Ivanchuk V; García-Campelo R; Dómine Gómez M; Sánchez JM; Massutí B; Reguart N; Camps C; Sanz-Moreno S; Calabuig-Fariñas S; Jantus-Lewintre E; Arnal M; Fernández-Orth D; Calvo V; González-Rumayor V; Provencio M; Romero A
Mol Oncol; 2021 Sep; 15(9):2363-2376. PubMed ID: 34058070
[TBL] [Abstract][Full Text] [Related]
40. Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy.
Press RH; Zhang C; Cassidy RJ; Ferris MJ; Zhong J; Steuer CE; Pillai RN; Owonikoko TK; Kahn S; Ramalingam SS; Patel PR; Curran WJ; Shu HG; Sica GL; Higgins KA
Cancer; 2018 Sep; 124(17):3586-3595. PubMed ID: 30120912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
